empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Significant effects of empagliflozin were not noted for the following outcomes: hs-CRP (SMD = −0.29, 95% CI = −0.85 to 0.26, p = 0.30), WBC count (SMD = −0.46, 95% CI = −1.58 to 0.66, p = 0.42), IL-6 (SMD = 0.43, 95% CI = −0.12 to 0.97, p = 0.12), ketone bodies (SMD = 2.95, 95% CI = −1.82 to 7.72, p = 0.23), HbA1c (SMD = −0.05, 95% CI = −0.38 to 0.29, p = 0.79), eGFR (SMD = 0.18, 95% CI = −0.16 to 0.51, p = 0.30), NT-proBNP (SMD = −0.19, 95% CI = −0.59 to 0.21, p = 0.35), E/e’ ratio (SMD = −0.55, 95% CI = −1.54 to 0.44, p = 0.28), TAPSE (SMD = 0.09, 95% CI = −0.12 to 0.30, p = 0.38), and DBP (SMD = −0.27, 95% CI = −0.60 to 0.07, p = 0.12).”
Quoted verbatim from Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily in eight included trials, 25 mg daily in one
- Population
- Patients with acute myocardial infarction; pooled RCTs, empagliflozin versus placebo; secondary outcome
Effect -0.29 standardised mean difference, 95% CI -0.85 to 0.26
Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.2025PMID:40489293Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against C-reactive protein concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45EE1FF3Y56DQVQDEN1V5AK